نبذة مختصرة : This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class 11 studies support the use of slow release valproic acid, clonazepan and oxycoclone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid. ; Univ Sao Paulo, Hosp Clin, Dept Neurol, Sao Paulo, Brazil ; Hosp Israelita Albert Einstein, Inst Cerebro, Sao Paulo, Brazil ; Pratica privada, Curitiba, Parana, Brazil ; Practica Privada, Rio De Janeiro, Brazil ; Univ Fed Minas Gerais, Dept Clin Med, Belo Horizonte, MG, Brazil ; Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil ; UNESP, Dept Neurol, Botucatu, SP, Brazil ; UFCE, Fortaleza, Ceara, Brazil ; Practica Privada, Porto Alegre, RS, Brazil ; Univ Fed Goias, Hosp Clin, Serv Neurol, Goiania, Go, Brazil ; Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil ; Web of Science
Processing Request
No Comments.